(Q33855495)

English

Recombinant interferon-Beta-1alpha plus ribavirin for the treatment of chronic HCV infection: a prospective, randomized, comparative pilot study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

Recombinant interferon-Beta-1alpha plus ribavirin for the treatment of chronic HCV infection: a prospective, randomized, comparative pilot study (English)

1 reference

Europe PubMed Central

29 July 2017

1 reference

based on heuristic

inferred from title

author name string

Sang Hoon Ahn

1

1 reference

Europe PubMed Central

29 July 2017

Hyun Woong Lee

2

1 reference

Europe PubMed Central

29 July 2017

Yong Soo Kim

3

1 reference

Europe PubMed Central

29 July 2017

Ja Kyung Kim

4

1 reference

Europe PubMed Central

29 July 2017

Kwang-Hyub Han

5

1 reference

Europe PubMed Central

29 July 2017

Chae Yoon Chon

6

1 reference

Europe PubMed Central

29 July 2017

Young Myoung Moon

7

1 reference

Europe PubMed Central

29 July 2017

publication date

31 March 2009

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

3

1 reference

Europe PubMed Central

29 July 2017

1

1 reference

Europe PubMed Central

29 July 2017

20-25

1 reference

Europe PubMed Central

29 July 2017

Spotlight on subcutaneous recombinant interferon-beta-1a (Rebif) in relapsing-remitting multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

28 July 2018

Challenges and successes in developing new therapies for hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

28 July 2018

Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

28 July 2018

Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

28 July 2018

Safety of interferon beta treatment for chronic HCV hepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

28 July 2018

Projecting future complications of chronic hepatitis C in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

28 July 2018

Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

28 July 2018

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

28 July 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

28 July 2018

Meta-analysis: combination therapy with interferon-alpha 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

28 July 2018

Interferon for interferon naive patients with chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

28 July 2018

Antiviral actions of interferons

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

28 July 2018

Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

28 July 2018

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

28 July 2018

Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

29 October 2018

Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

29 October 2018

Hepatitis C: it's a long way to new therapy, it's a long way to go...

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

29 October 2018

Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

29 October 2018

Differences in treatment outcome for hepatitis C among ethnic groups

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

29 October 2018

Diagnosis, management, and treatment of hepatitis C

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

29 October 2018

Twice-a-day versus once-a-day interferon-beta therapy in chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

29 October 2018

Side effects of therapy of hepatitis C and their management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

29 October 2018

Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

29 October 2018

A pilot study of recombinant interferon beta-1a for the treatment of chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

29 October 2018

Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

29 October 2018

Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group Investigators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

29 October 2018

Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

29 October 2018

Clinical efficacy of intramuscular human interferon-beta vs interferon-alpha 2b for the treatment of chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2871561

29 October 2018

Tolerance and efficacy of subcutaneous interferon-beta administered for treatment of chronic hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/20479896

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resolution of acute hepatitis C after therapy with natural beta interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/20479896

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update

1 reference

https://pubmed.ncbi.nlm.nih.gov/20479896

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/20479896

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.5009/GNL.2009.3.1.20

1 reference

Europe PubMed Central

29 July 2017

PMC publication ID

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33855495&oldid=1534018971"